Navigation Links
University of Colorado Cancer Center Study Shows the Preferred Feeding Method is not the Medically Best in Malnourished Pediatric Cancer Patients
Date:2/13/2013

Aurora, Colo (PRWEB) February 13, 2013

About 60 percent of pediatric cancer patients experience malnourishment during treatment. At that point, patients and families have a choice: tube feeding or IV nutrition supplement. Which would you choose? A study published this week in the Journal of Pediatric Oncology Nursing shows that families’ perceptions, especially of the discomfort of tube feeding, leads to choosing IV over tube – despite the fact that tube feeding is usually the better choice, associated with better gut function and lower rates of infection.

“Despite the benefits of tube feeding, we found a strong preference among families and older pediatric patients for IV feeding,” says Kitty Montgomery, MS, RN, PCNS-BC, CPHON, the study’s senior author and pediatric clinical nurse specialist at Children’s Hospital Colorado, a clinical care partner of the University of Colorado Cancer Center.

The study surveyed 49 parents and older pediatric cancer patients. Of 14 patients, all reported preferring IV feeding over tube feeding, for example saying, “I already had a port in for chemo, so we used that for TPN,” and, “Tube feeding sounds disgusting and uncomfortable.”

“When nutrition support is needed, most health care teams suggest tube-feeding first. Only, we tend to find resistance to the idea from parents or patients,” Montgomery says. “This study shows us the reasons for those objections and we hope will help us learn to break down those barriers to the best method of support.”

Parents of pediatric cancer patients were much more evenly split between preference for tube feeding (41 percent) and IV feeding (59 percent), with the parents who preferred tube feeding frequently citing information about the procedure given by the treatment team as the reason for their choice. For example, one parent said, “Tube feeding is helpful in giving meds and not as hard on the liver and keeps the digestive system working properly.” Another parent who preferred tube feeding said they, ”Chose tube feedings because it helped to keep digestive system active, making it easier to adjust back to food.”

“This helps us tailor our message,” says Montgomery. “We see now that the biggest barrier to tube feeding is perceived discomfort, so health care professionals may have better success with patients and parents by addressing that issue. What we need to do now is learn to translate these findings into action.”

The authors received financial support from the Rebecca Slye Endowment Grant to conduct the research.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10429284.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. University of Colorado Cancer Center Study Shows That Problem-Solving Training Helps Mothers Cope with Child’s Cancer Diagnosis
2. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
3. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
4. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
5. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
6. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
7. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
8. Notre Dame to be part of $194 million university research center network
9. University of Minnesota awarded $28 million grant to lead microelectronics development
10. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
11. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):